No Detail Found!

Comparative in Vitro Efficacy of Doripenem and Imipenem against Multi-drug Resistant Pseudomonas aeruginosa.

Author(s)
Nadia Wali Department of Microbiology, Foundation University Medical College, Rawalpindi, Pakistan
Irfan Ali Mirza Department of Microbiology, Pakistan Navy (PN) Shifa Hospital, Karachi, Pakistan
Abstract
Objective: To compare the in vitro efficacy of doripenem and imipenem against multi-drug resistant (MDR) Pseudomonas aeruginosa from various clinical specimens. Study Design: Descriptive cross-sectional study. Place and Duration of Study: Department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi, from November 2012 to November 2013. Methodology: MDR Pseudomonas aeruginosa isolates from various clinical samples were included in the study. Susceptibility of Pseudomonas aeruginosa against doripenem and imipenem was performed by E-test strip and agar dilution methods. The results were interpreted as recommended by Clinical Laboratory Standard Institute (CLSI) guidelines. Results: The maximum number of Pseudomonas aeruginosa were isolated from pure pus and pus swabs. In vitro efficacy of doripenem was found to be more effective as compared to imipenem against MDR Pseudomonas aeruginosa with both E-test strip and agar dilution methods. Overall, p-values of 0.014 and 0.037 were observed when susceptibility patterns of doripenem and imipenem were evaluated with E-test strip and agar dilution methods. Conclusion: In vitro efficacy of doripenem was found to be better against MDR Pseudomonas aeruginosa as compared to imipenem when tested by both E-test and agar dilution methods.
Publication Details
Page(s) 297-301
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 26, Issue: 4, Year: 2016

Request the full text from PASTIC

References
KerrKG,SnellingAM, 2009.Pseudomonas aeruginosa: a formidable and ever-present adversary,J Hosp Infec 73 338 -44
OkamotoK,GotohN,NishinoT., 2001.Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay,Antimicrob Agents Chemother 45 1964 -71
AloushV,Navon-VeneziaS,Seigman-IgraY,CabiliS,CarmeliY, 2006.Multidrug-resistant Pseudomonas aeruginosa: Risk factors and clinical impact,Antimicrob Agents Chemother 50 43 -8
MagiorakosAP,SrinivasanA,CareyRB,CarmeliY,FalagasME,GiskeCG, 2011.Multidrug-resistant, extensively drugresistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance,Clin Microbiol Infect 18 268 -81
AminNE,GiskeCG,JalalShah,KeijserB,KronvallG,WretlindB, 2005.Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates,APMIS 113 187 -96
Papp-WallaceKM,EndimianiA,TaracilaMA,BonomoRA, 2011.Carbapenems: past, present and future,Antimicrob Agents Chemother 55 4943 -60
Alvarez-LermaF,GrauS,FerrándezO, 2009.Characteristics of doripenem: a new broad-spectrum antibiotic,Drug Des Devel Ther 3 173 -90
PillarCM,TorresMK,BrownNP,ShahD,Sahm DF, 2008.In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by Gram-negative bacteria, against recent clinical isolates from the United States,Antimicrob Agents Chemother 52 4388 -99
PatersonDL,DepestelDD, 2009.,Clin Infect Dis 49 291 -8
HenryDA,SpeertDP,WarnockDW,CarrollKC,FunkeG, 2011.,Manual of clinical microbiology 677 -80
2013.Clinical and Laboratory Standard Institute (CLSI). Performance standard for antimicrobial susceptibility testing; twenty-third informational supplement M100-S23, 27 14 -8
2015.,2015 [Cited -
PatelJB,TenoverFC,TurnidgeJD,JorgensenJH,WarnockDW,CarrollKC,FunkeG, 2011.Susceptibility testing methods: dilution and disk diffusion methods,Manual of clinical microbiology 1126 -7
HirschEB,TamVH, 2010.Impact of multi-drug resistant Pseudomonas aeruginosa infection on patient outcomes,Expert Rev Pharmacoecon Outcomes Res 10 441 -51
SattiL,AbbasiS,QumarTA,KhanMS,ZA.,R J, 2011.In vitro efficacy of cefepime against multi-drug resistant Pseudomonas aeruginosa: An alarming situation in our setup, 1 12 -6
ParmarH,DholakiaA,VasavadaD,SinghalaH., 2013.The current status of antibiotic sensitivity of Pseudomonas aeruginosa isolated from various clinical samples,Int J Res Med 2 1 -6
NadeemSG,QasmiSA,AfaqueF,SaleemM,HakimST, 2009.Comparison of in vitro susceptibility of clinical isolates of Pseudomonas aeruginosa in a local hospital setting in Karachi, Pakistan,BJMP 2 35 -9
SomilyAM,AbsarMM,ArshadMZ,Al-AskaAI,ShakoorZA,FataniAJ, 2012.Antimicrobial susceptibility patterns of multi-drug resistant Pseudomonas aeruginosa and Acinetobacter baumannii against carbapenems, colistin and tigecycline,Saudi Med J 33 750 -55
DrzewieckiA,BulandaM,TalagaK,SodoA,AdamskiP, 2012.Comparison of in vitro activity of doripenem, imipenem and meropenem against clinical isolates of Entero-bacteriaceae, Pseudomonas and Acinetobacter in Southern Poland,Polskiprzeglad Chirurgiczny 84 449 -53
LeblebiciogluH,CakirN,CelenM,KurtH,BarisH,LaefurrJ, 2012.Comparative activity of carbapenem testing (the COMPACT study) in Turkey,BMC Infect Dis 12 2334 -42
LeeH,KoKS,SongJH,PeckKR, 2011.Antimicrobial activity of doripenem and other carbapenems against Gram-negative pathogens from Korea,Microb Drug Resist 17 37 -45
GimenoC,CantónR,GarcíaA,GobernadoM, 2010.Comparative activity of doripenem, meropenem and imipenem in recent clinical isolates obtained during the COMPACT-Spain epidemiological surveillance study,Rev Esp Quimioter 23 144 -52
GoldsteinJC,CitronDM,MerriamCV,WarrenYA,TyrrellKL,FernandezHT, 2008.In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds,Antimicrob Agents Chemother 52 761 -6
LouieA,BiedA,FregeauC,ScoyBV,BrownD,LiuW, 2010.Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance,Antimicrob Agents Chemother 54 2638 -45
SahmD., 2012.In vitro activity of doripenem,Clin Infect Dis 49 11 -6
GreerND, 2008.Doripenem (Doribax): the newest addition to the carbapenems,Proc Bayl Univ Med Cent 21 337 -41
0

Citations

0

Downloads

77

Views